While the clinical and case studies (Table 2) show the occurrence of CD74-ROS1 in many patients with relapsed, advanced stage cancer (III–IV), the retrospective studies conducted on patient tumor samples (Table S1) reveal that many CD74-ROS1 fusions can be detected at earlier cancer stages (I–II). Here, ROS1 is linked to neoplasm.